Show simple item record

dc.contributor.authorCherry, C.
dc.contributor.authorRosenow, A.
dc.contributor.authorAffandi, J.
dc.contributor.authorMcArthur, J.
dc.contributor.authorWesselingh, S.
dc.contributor.authorPrice, Patricia
dc.date.accessioned2017-01-30T13:50:08Z
dc.date.available2017-01-30T13:50:08Z
dc.date.created2016-09-12T08:36:57Z
dc.date.issued2008
dc.identifier.citationCherry, C. and Rosenow, A. and Affandi, J. and McArthur, J. and Wesselingh, S. and Price, P. 2008. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk. AIDS Research and Human Retroviruses. 24 (2): pp. 117-123.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/35531
dc.identifier.doi10.1089/aid.2007.0168
dc.description.abstract

Nucleoside analog-associated sensory neuropathy (NRTI-SN) attributed to stavudine, didanosine, or zalcitabine (the dNRTIs) and distal sensory polyneuropathy (DSP) attributed to HIV are clinically indistinguishable. As inflammatory cytokines are involved in DSP, we addressed a role for inflammation in NRTI-SN by determining the alleles of immune-related genes carried by patients with and without NRTI-SN. Demographic details associated with risk of various neuropathies were included in the analysis. Alleles of 14 polymorphisms in 10 genes were determined in Australian HIV patients with definite NRTI-SN (symptom onset <6 months after first dNRTI exposure, n = 16), NRTI-SN-resistant patients (no neuropathy despite >6 months on dNRTIs, n = 20), patients with late onset NRTI-SN (neuropathy onset after >6 months of dNRTIs, n = 19), and HIV-negative controls. Carriage of TNFA-1031*2 was highest in NRTI-SN patients, suggesting potentiation of NRTI-SN. Carriage of IL12B (3' UTR)*2 was higher in NRTI-SN-resistant patients than controls or NRTI-SN patients, suggesting a protective role. BAT1 (intron 10)*2 was more common in NRTI-SN than resistant patients, but neither group differed from controls. This marks the conserved HLA-A1, B8, DR3 haplotype. Of the demographic details considered, increasing height was associated with NRTI-SN risk. A model including cytokine genotype and height predicted NRTI-SN status (p < 0.0001, R2 = 0.54). Late onset NRTI-SN patients clustered genetically with NRTI-SN-resistant patients, so these patients may be genetically "protected." In addition to patient height, cytokine genotype influenced NRTI-SN risk following dNRTI exposure, suggesting inflammation contributes to NRTI-SN. © 2008 Mary Ann Liebert, Inc.

dc.publisherMary Ann Liebert, Inc.
dc.titleCytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk
dc.typeJournal Article
dcterms.source.volume24
dcterms.source.number2
dcterms.source.startPage117
dcterms.source.endPage123
dcterms.source.issn0889-2229
dcterms.source.titleAIDS Research and Human Retroviruses
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record